Xenon Pharmaceuticals Inc. - Common Shares (XENE)
CUSIP: 98420N105
Q3 2016 13F Holders as of 30 Sep 2016
- Type / Class
- Equity / Common Shares
- Shares outstanding
- 92,799,600
- Total 13F shares
- 9,943,719
- Share change
- +4,567,997
- Total reported value
- $80,586,000
- Price per share
- $8.10
- Number of holders
- 31
- Value change
- +$37,001,698
- Number of buys
- 18
- Number of sells
- 4
Quarterly Holders Quick Answers
What is CUSIP 98420N105?
CUSIP 98420N105 identifies XENE - Xenon Pharmaceuticals Inc. - Common Shares in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 98420N105:
Top shareholders of XENE - Xenon Pharmaceuticals Inc. - Common Shares (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| BVF INC/IL |
13F
|
Company |
1.9%
|
1,775,572
|
$10,511,000 | — | 30 Jun 2016 | |
| Capital World Investors |
13F
|
Company |
1.1%
|
1,030,000
|
$6,098,000 | — | 30 Jun 2016 | |
| Invesco Private Capital, Inc. |
13F
|
Company |
0.47%
|
436,384
|
$2,575,000 | — | 30 Jun 2016 | |
| PERCEPTIVE ADVISORS LLC |
13F
|
Company |
0.47%
|
432,800
|
$2,553,000 | — | 30 Jun 2016 | |
| Opaleye Management Inc. |
13F
|
Company |
0.44%
|
410,000
|
$2,419,000 | — | 30 Jun 2016 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0.42%
|
392,484
|
$2,315,000 | — | 30 Jun 2016 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
0.39%
|
358,531
|
$2,115,000 | — | 30 Jun 2016 | |
| DAFNA Capital Management LLC |
13F
|
Company |
0.23%
|
214,091
|
$1,263,000 | — | 30 Jun 2016 | |
| Novo Holdings A/S |
13F
|
Company |
0.14%
|
127,563
|
$753,000 | — | 30 Jun 2016 | |
| State of New Jersey Common Pension Fund D |
13F
|
Company |
0.07%
|
65,000
|
$385,000 | — | 30 Jun 2016 | |
| Leith Wheeler Investment Counsel Ltd. |
13F
|
Company |
0.02%
|
17,869
|
$370,000 | — | 30 Jun 2016 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.05%
|
48,500
|
$286,000 | — | 30 Jun 2016 | |
| Weiss Multi-Strategy Advisers LLC |
13F
|
Company |
0.03%
|
32,400
|
$191,000 | — | 30 Jun 2016 | |
| NJ State Employees Deferred Compensation Plan |
13F
|
Company |
0.02%
|
20,000
|
$118,000 | — | 30 Jun 2016 | |
| BANK OF MONTREAL /CAN/ |
13F
|
Company |
0.01%
|
7,137
|
$42,000 | — | 30 Jun 2016 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0%
|
3,646
|
$21,000 | — | 30 Jun 2016 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0%
|
2,925
|
$17,000 | — | 30 Jun 2016 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0%
|
886
|
$6,000 | — | 30 Jun 2016 | |
| MORGAN STANLEY |
13F
|
Company |
0%
|
917
|
$5,000 | — | 30 Jun 2016 | |
| CITIGROUP INC |
13F
|
Company |
0%
|
700
|
$4,000 | — | 30 Jun 2016 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0%
|
111
|
$1,000 | — | 30 Jun 2016 |
Institutional Holders of Xenon Pharmaceuticals Inc. - Common Shares (XENE) as of Q3 2016
As of 30 Sep 2016,
Xenon Pharmaceuticals Inc. - Common Shares (XENE) was held by
31 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
9,943,719 shares.
The largest 10 holders included
BVF INC/IL, Capital World Investors, ORBIMED ADVISORS LLC, PERCEPTIVE ADVISORS LLC, Tekla Capital Management LLC, DAFNA Capital Management LLC, Invesco Private Capital, Inc., Opaleye Management Inc., ROYAL BANK OF CANADA, and Point72 Asset Management, L.P..
This page lists
31
institutional shareholders reporting positions in this security
for the Q3 2016 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2016 vs Q2 2016 Across Filers
Q2 2016 holders
21
Q3 2016 holders
31
Holder diff
10
| Investor | Q2 2016 Shares | Q3 2016 Shares | Share Diff | Share Chg % | Q2 2016 Value $ | Q3 2016 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.